Investment Analysts’ Weekly Ratings Updates for NovoCure (NVCR)

A number of firms have modified their ratings and price targets on shares of NovoCure (NASDAQ: NVCR) recently:

• 11/10/2026 – NovoCure had its price target raised by Ladenburg Thalmann & Co. Inc. from $27.00 to $31.00. They now have a “buy” rating on the stock.
• 11/10/2026 – NovoCure had its price target lowered by Wedbush from $20.00 to $19.00. They now have a “neutral” rating on the stock.
• 10/31/2026 – NovoCure was upgraded by Wall Street Zen from “hold” to “buy”.
• 10/30/2026 – NovoCure was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
• 10/30/2026 – NovoCure had its price target lowered by Wells Fargo & Company from $20.00 to $15.00. They now have an “equal weight” rating on the stock.
• 10/10/2026 – NovoCure was downgraded by Wall Street Zen from “buy” to “hold”.

NovoCure Stock Down 2.3%

Shares of NASDAQ:NVCR opened at $11.72 on Friday. The company’s fifty day moving average is $14.95 and its 200-day moving average is $14.75. The company has a debt-to-equity ratio of 0.49, a quick ratio of 2.34 and a current ratio of 2.49. NovoCure Limited has a 52 week low of $9.82 and a 52 week high of $21.45. The company has a market capitalization of $1.37 billion, a PE ratio of -11.06 and a beta of 1.09.

NovoCure (NASDAQ:NVCR) last announced its earnings results on Thursday, October 29th. The medical equipment provider reported ($0.09) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.14. NovoCure had a negative net margin of 16.78% and a negative return on equity of 35.81%. The business had revenue of $193.40 million during the quarter, compared to analysts’ expectations of $182.28 million. During the same quarter last year, the company posted ($0.33) EPS. The firm’s revenue for the quarter was up 15.7% on a year-over-year basis. Equities research analysts predict that NovoCure Limited will post -1.10 earnings per share for the current fiscal year.

NovoCure is a global oncology company that develops and commercializes Tumor Treating Fields (TTFields), a cancer treatment that uses wearable devices to deliver low-intensity electric fields intended to disrupt cancer cell division. Its products include Optune Gio and Optune Lua, which are used to treat certain cancers. The company is headquartered in Baar, Switzerland, and serves patients in markets across North America, Europe and Asia. NovoCure was founded in 2000 by Yoram Palti, a medical researcher who developed the TTFields approach.